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A
 
BSTRACT
 
There is increasing evidence that an exaggerated
accumulation of activated neutrophils is linked to the
clinical course of obstructive airway diseases, such as
asthma and chronic obstructive pulmonary disease.
The present review article focuses on the evidence that
the T cell cytokine interleukin (IL)-17 plays a role in
orchestrating the accumulation and subsequent acti-
vation of neutrophils in the airways and lungs. The
mechanistic roles of neutrophils and IL-17 in obstruc-
tive airway disease are discussed. It is concluded that
targeting IL-17 may consitute a potential strategy for
developing novel pharmacotherapeutic interventions
against obstructive airway disease.
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I
 
NTRODUCTION
 
There is now increasing evidence that the cytokine
interleukin (IL)-17 (also named ‘IL-17A’) plays a pro-
inflammatory role in the immune system; this evidence
has emerged during the 10 years that have passed since
the discovery of this intriguing cytokine.
 
1,2
 
 The first study
focusing on the effects of IL-17 protein in the airways
 
3
 
has now been followed by several other studies that have
improved the understanding of the biology of IL-17 and
its potential role in airway inflammation. The present
review focuses on the evidence that IL-17 plays a role in
orchestrating the accumulation and subsequent activa-
tion of neutrophils in the airways and lungs.
 
A
 
CCUMULATION
 
 
 
OF
 
 
 
NEUTROPHILS
 
 
 
IN
 
 
 
AIRWAY
 
 
 
AND
 
 
 
LUNG
 
 
 
DISEASE
 
The accumulation and activation of neutrophils in the
airways and lungs is linked to the course of several
inflammatory diseases, including obstructive airway
diseases, such as asthma and chronic obstructive pul-
monary disease (COPD), and related conditions, such
as non-specific bronchial hyperreactivity and chronic
bronchitis.
 
4–19
 
 The evidence cited has been obtained
through characterization of the number of neutrophils
present in airway and lung tissue, in bronchoalveolar
lavage (BAL) fluid, in induced sputum and in blood.
 
A
 
CCUMULATION
 
 
 
OF
 
 
 
NEUTROPHILS
 
 
 
AND
 
 
 
FUNCTION
 
 
 
OF
 
 
 
AIRWAYS
 
 
 
AND
 
 
 
LUNGS
 
The number of neutrophils in the airway lumen corre-
lates negatively with non-specific airway reactivity in
patients with mild asthma.
 
19
 
 Interestingly, the number of
neutrophils in the airway lumen and mucosa also
correlates negatively with lung function in smokers with
or without chronic bronchitis or COPD.
 
10,15–17
 
 Among
smokers, the number of luminal neutrophils correlates
positively with the annual decline in lung function.
 
20
 
 It is
also known that neutrophil recruitment is associated
with  bronchial hyperresponsiveness in rodent airways
 
in vivo.
 
21
 
 Thus, it is possible that the accumulation of
neutrophils exerts a functional impact on the airways in
asthma and COPD.
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N
 
EUTROPHILS
 
 
 
PRODUCE
 
 
 
PATHOGENETICALLY
 
 
 
RELEVANT
 
 
 
COMPOUNDS
 
The fact that neutrophils are capable of releasing
bioactive compounds that can cause functional altera-
tions in the airways and lungs is interesting because
these functional alterations resemble those observed in
obstructive airway diseases, such as asthma and COPD.
Neutrophil elastase is an example of a proteolytic
enzyme that can be released from neutrophils in the air-
ways. As indicated by its name, elastase degrades elastin,
a structural component of the lungs, and it has been
shown that the deposition of exogenous elastase in
rodent airways leads to emphysema-like alterations in the
lungs and tissue remodeling in the airways 
 
in vivo.
 
22–26
 
Neutrophil elastase also alters the structure of collagen
gels 
 
in vitro.
 
26
 
 Indeed, neutrophil elastase is a potent
inducer of secretion by gland cells in rodent airways
 
27,28
 
and it can cause bronchial hyperresponsiveness in
murine airways 
 
in vivo.
 
22,23
 
 In view of these findings, it is
of special interest that neutrophil elastase can be
detected in obstructive airway disease.
Neutrophil elastase is detected in the submucosa
of bronchi of patients with severe asthma, regardless of
whether eosinophils are present.
 
9
 
 Furthermore, even when
there is no detectable airway infection present, the luminal
concentration of neutrophil elastase is increased in severe
asthma.
 
5–7
 
 Similarly, an increased luminal concentration of
elastase is observed in chronic bronchitis and COPD.
 
26
 
There is also evidence consistent with this elastase actually
having a functional impact; the luminal concentration of
this proteolytic enzyme correlates negatively with lung
function in asthma and chronic bronchitis.
 
6
 
Certain evidence puts forward some matrix metallo-
proteases (MMP) as neutrophil-derived compounds
contributing to the pathogenesis of obstructive airway
disease in the airway and lungs.
 
30,31
 
 Thus, the luminal
concentration of MMP-8 and -9 is increased in asthma
and COPD, respectively.
 
30,32–34
 
 Interestingly, the luminal
concentration of MMP-8 correlates negatively with lung
function in patients with asthma and MMP-9 appears to
mediate allergen-induced airway hyperresponsiveness in
sensitized rodents 
 
in vivo.
 
30,35
 
In addition to proteolytic enzymes, neutrophils can
produce oxygen free radicals and neutrophils from
patients with asthma display increased production of
these cytotoxic compunds.
 
36–38
 
 There is also evidence that
oxygen free radicals can induce the transcription of
mRNA for neutrophil-recruiting cytokines, such as the
neutrophil chemoattractant IL-8, leading to subsequent
IL-8 protein release and perpetuation of neutrophil
recruitment.
 
39,40
 
 Hypotheticallly, these events may con-
tribute to airway remodeling and altered lung function.
In line with this, there is evidence that oxygen free radi-
cals contribute to bronchial hyperresponsiveness and
that this phenomenon involves neutrophils under certain
conditions in mammals 
 
in vivo.
 
22,41–44
 
 Furthermore, con-
ditioned medium from human neutrophils can increase
the reactivity of human bronchial smooth muscle 
 
in vitro
 
,
but it remains to be confirmed whether this particular
effect is mediated by oxygen free radicals.
 
45
 
Neutrophils can also perpetuate their own accumula-
tion through the production and release of compunds
that, 
 
per se
 
, recruit even more neutrophils. These com-
pounds include leukotriene B
 
4
 
, tumor necrosis factor
(TNF)-
 
α
 
 and IL-8.
 
46–54
 
 Interestingly, there is evidence to
support that both TNF-
 
α
 
 and IL-8 cause bronchial hyper-
responsiveness in rodent airways 
 
in vivo
 
.
 
40,55,56
 
 It may be
that this TNF-
 
α
 
 perpetuates additional neutrophil recruit-
ment via the stimulation of IL-8 in bronchial epithelial
cells.
 
39,57,58
 
 The fact that the luminal concentration of IL-8
correlates negatively with bronchial reactivity in patients
with mild asthma
 
19
 
 is, indeed, compatible with neutro-
phils exerting a functional impact in obstructive airway
disease.
To summarize, there is evidence that neutrophils can
contribute to gland hypersecretion, bronchoconstriction
and bronchial hyperreactivity, as well as tissue destruc-
tion in lungs and aiway remodeling in obstructive airway
disease. Neutrophils can also perpetuate the additional
accumulation of neutrophils at the inflammatory site and
this type of local accumulation of neutrophils seems to
exert a functional impact on the airways and lungs. For
these reasons, the endogenous mechanisms orchestrat-
ing the accumulation and activation of neutrophils con-
stitute potential targets for novel pharmacotherapy.
 
O
 
RCHESTRATION
 
 
 
OF
 
 
 
NEUTROPHILS
 
 
 
IN
 
 
 
THE
 
 
 
AIRWAYS
 
 
 
AND
 
 
 
LUNGS
 
A number of different cell types in the bronchial wall,
airway lumen and post-capillary venules can release
chemoattractant signals to neutrophils, such as IL-8 and
other C-X-C chemokines. Thus, bronchial epithelial
cells, bronchial smooth muscle cells, fibroblasts, macro-
phages/monocytes, neutrophils themselves and even
eosinophils have the potential to contribute to neutrophil
recruitment by releasing IL-8 in asthma and chronic
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bronchitis.
 
39,57–63
 
 It remains unknown how these cells are
coordinated to orchestrate neutrophil accumulation, in
particular because chemokines are believed to function
by establishing concentration gradients.
 
T L
 
YMPHOCYTES
 
 
 
AND
 
 
 
THE
 
 
 
ACCUMULATION
 
 
 
OF
 
 
 
NEUTROPHILS
 
There is convincing evidence that certain T lymphocytes
orhestrate the recruitment and activation of granulocytes
in the airways and lungs, in particular for CD4
 
+
 
 lympho-
cytes and eosinophilic granulocytes. Thus, in the airways
of patients with newly diagnosed asthma, the total
number of lymphocytes, eosinophils and neutrophils is
increased.
 
64
 
 Specific blockade of lymphocytes with an
anti-CD4
 
+
 
 antibody or an anti-IL-2 receptor antibody
does prevent allergen-induced recruitment of eosino-
phils and neutrophils, respectively, in the airways of
sensitized rodents 
 
in vivo.
 
65,66
 
 In addition, in the airways
of certain patients with COPD, there is an accumulation
of both CD4
 
+
 
 lymphocytes and neutrophils.
 
67,68
 
 Further-
more, exposure to cigarette smoke causes an accumula-
tion of CD4
 
+
 
 lymphocytes and neutrophils in rodent
airways 
 
in vivo.
 
69
 
 The accumulation of CD4
 
+
 
 lympho-
cytes also relates to functional changes in the airways;
the presence of CD4
 
+
 
 lymphocytes is related to bron-
chial reactivity in the airways of humans and rodents
 
in vivo
 
, even though it is not known whether this phe-
nomenon relates to the orchestration of eosinophils,
neutrophils or both.
 
70–72
 
 Importantly, the mechanisms
linking CD4
 
+
 
 lymphocytes to the accumulation of neutro-
phils have remained unclear. This lack of knowledge
about mechanisms is in sharp contrast with the vast
knowledge about the mechanistic links between CD4
 
+
 
lymphocytes and eosinophils in the airways and lungs,
where Th2 cytokines, such as IL-3, IL-4 and IL-5, as well
as the growth factor granulocyte–macrophage colony
stimulating factor (GM-CSF), are believed to play impor-
tant roles.
 
73–77
P
 
RODUCTION
 
 
 
OF IL-17 BY T LYMPHOCYTES 
IN VITRO
The homodimer IL-17 is a 155 amino acid molecule
with a molecular weight ranging from 15 to 22 kDa.78
Rodent IL-17 displays a substantial structural homology
with human IL-17: the glycosylation site is highly con-
served, a fact that is compatible with IL-17 being
important for the mammalian immune system.78
As judged from studies on spleen or blood cells
in vitro, human and rodent CD4+ lymphocytes can pro-
duce, and subsequently release, IL-17 protein when acti-
vated in vitro.2,78,79 Of particular interest for inflammatory
disease in the airways and lungs, it was recently demon-
strated that CD3+ lymphocytes from rodent lungs can
produce free soluble IL-17 protein in vitro.80 In line with
IL-17 being produced by both CD8+ and CD4+ lym-
phocytes, memory T lymphocytes (CD45RO) of both
these subsets may account for the production of IL-17
protein, as indicated in lymphocytes isolated from the
blood of healthy human volunteers and studied in vitro.81
It has also been claimed that IL-17 is produced mainly by
the Th0 and Th1 lymphocyte subsets in vitro, based on
findings in synovial CD4+ cells from patients with rheu-
matoid arthritis.82 In one study only, it has been claimed
that eosinophils constitute a source of IL-17 protein, but
to date there is no published functional evidence that
eosinophils can release free soluble IL-17 protein in vitro
or in vivo.83 Taken together, most published evidence
favors the idea that, in the airways, IL-17 protein is not
released during physiological conditions.78,84
THE RECEPTOR FOR IL-17
The human receptor for IL-17 displays a unique struc-
ture; it is a type I membrane protein containing a 293
amino acid extracellular domain, a 21 amino acid
transmembrane domain and a 525 amino acid cyto-
plasmic tail.78,79,85–87 The mRNA for the human IL-17
receptor is expressed in a wide range of cells, including
airway epithelial cells, foreskin and synovial fibroblasts,
B and T lymphocytes and myelomonocytic cells.85–87 In
line with this, the mRNA for the rodent IL-17A receptor is
present in rodent lungs, kidneys, liver and spleen.85,86
Rodent cells such as fibroblasts, intestinal epithelial cells
and various T lymphocyte clones also express mRNA for
the rodent IL-17A receptor.85,86 Of note, the IL-17
receptor protein appears to be expressed constitutively in
several of these human and rodent cells, indicating a
general ‘readiness’ to respond to IL-17 under physio-
logical conditions.
NEUTROPHIL-MOBILIZING FACTORS INCREASED 
IN AIRWAY EPITHELIAL CELLS BY IL-17
Various human airway epithelial cells respond to stimu-
lation with human IL-17 protein in vitro by producing
and releasing the C-X-C chemokine IL-8.3,88–91 The
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same is true for the release of the C-X-C chemokines
growth-related oncogene (GRO)-α and granulocyte
chemotactic protein (GCP)-2.91,92 In the case of IL-8
and GRO-α, this chemokine production is probably
specific because it is attenuated if the human IL-17
protein is coincubated with an antihuman IL-17 anti-
body.3,92 In terms of gene expression, as well as protein
release, human IL-17 protein increases IL-8 and GRO-α
to a similar degree as does TNF-α.92 Interestingly, there
are functional data showing that conditioned cell
medium from human airway epithelial cells stimulated
with human IL-17 protein does cause neutrophil chemo-
taxis in vitro.3 It appears as if the major part of this effect
is mediated via IL-8, because preincubation of the
conditioned medium with an antihuman IL-8 antibody
attenuates the chemotactic activity of the cell medium
and human IL-17 protein per se does not cause chemo-
taxis for human blood neutrophils in vitro.
Treatment with a glucocorticoid (hydrocortisone)
attenuates the induced release of C-X-C chemokines,
such as IL-8, GRO-α and GCP-2, caused by human
IL-17 protein in human airway epithelial cells in vitro.3,89,91
However, there are conflicting data suggesting that the
IL-17-induced IL-8 release in human airway epithelial
cells, as opposed to TNF-α-induced IL-8 release, is resist-
ant to a glucocorticoid (dexamethasone) under certain
conditions.92 The basis for this discrepancy remains
unclear, but it may relate to the fact that, in the specific
study mentioned, epithelial cells were cultured in the
presence of a glucocorticoid prior to the re-addition of a
glucocorticoid.
Interestingly, it appears as if IL-17-induced release of
IL-8, but not of GCP-2 or GRO-α, is potentiated by the
β2-adrenergic receptor agonist salbutamol in human
bronchial epithelial cells in vitro.91 Thus, this observation
is compatible with a selective and potentially proinflam-
matory effect on neutrophil recruitment being caused by
a β2-adrenergic receptor agonist, but it remains to be
confirmed whether this is the basis for a corresponding
effect in airways in vivo.57,93–95
It is not yet certain whether the IL-17-induced release
of IL-8 and other C-X-C chemokines in human airway
epithelial cells involves a nuclear factor (NF)-κB-inducing
kinase, as it does in intestinal epithelial cells in vitro.96
However, it seems likely that it does, because NF-κB
is  involved in initiating the transcription of IL-8 in
response to a variety of stimuli other than IL-17 in airway
epithelial cells, including oxygen free radicals, bacterial
products and particulate matter.97–101 The role of
mitogen-activated protein kinases (MAPK) is more cer-
tain; several studies have indicated that these kinases are
involved in mediating the intracellular response to IL-17,
a response that subsequently leads to the release of
C-X-C chemokines in human airway epithelial cells.89,91,92
Thus, an inhibitor of the MAPK p38 attenuates IL-17-
induced release of IL-8 and the same is true for an inhib-
itor of the MAPK extracellular signal-regulated kinase
(ERK) in transformed human airway epithelial cells in
vitro, even though only the involvement of ERK has been
confirmed in primary human airway epithelial cells
in vitro.89,90
It is also interesting that IL-17 is capable of interacting
with other proinflammatory cytokines when causing the
release of C-X-C chemokines. Thus, costimulation of
human airway epithelial cells with the Th1 cytokine
TNF-α substantially augments the release of C-X-C
chemokines, such as IL-8 and GRO-α, compared with
stimulation with IL-17 alone.3,92 Similarly, costimulation
of human airway epithelial cells with the Th1 cytokine
interferon (IFN)-γ augments the IL-17-induced release of
IL-8 in human airway epithelial cells.90 Costimulation with
the Th2 cytokines IL-4 or IL-13 also augments IL-17-
induced IL-8 release in these cells.90
Human airway epithelial cells also respond to stimula-
tion with human IL-17 by releasing the potentially
neutrophil-activating cytokine IL-6 in vitro.85,88–90,92 Just
as for IL-8, the intracellular pathways appear to involve
MAPK, even though there are conflicting data on
the involvement of the particular MAPK p38, whereas the
involvement of ERK has been confirmed in transformed
and primary human airway epithelial cells.88,89 Again,
costimulation with the Th1 cytokine IFN-γ augments
the release of IL-6.90 It remains unknown whether this
type of IL-6 release is sensitive to a glucocorticoid or a
β2-adrenergic receptor agonist.
There is also evidence that IL-17 can stimulate the
release of growth factors in human airway epithelial cells
under certain conditions.92,102 In these epithelial cells,
IL-17 releases granulocyte colony stimulating factor
(G-CSF) as well as GM-CSF in vitro and the effects of
IL-17 on the release of G-CSF and GM-CSF proteins are
of a similar order of magnitude as seen with TNF-α.92,102
Similarly, in terms of gene expression, IL-17 increases
G-CSF to a similar degree as does TNF-α.92 In the case
of the release of G-CSF protein, costimulation with TNF-α
causes a truly synergistic effect compared with stimulation
with IL-17 alone92 in human airway epithelial cells. This
seems to be true for GM-CSF also.102 Furthermore, there
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are data suggesting that the effect of IL-17 on GM-CSF
protein is functionally relevant in terms of increasing the
survival of human neutrophils, at least in vitro.102
Compared with TNF-α, stimulation with IL-17 alone
does not cause any substantial increase in expression of
the gene or mRNA for intracellular adhesion molecule
(ICAM)-1 in human airway epithelial cells in vitro.90 Nor
does IL-17 increase ICAM-1 protein in these cells.90
However, costimulation of human airway epithelial cells
with human IL-17 plus the Th1 cytokine IFN-γ does cause
a marked increase in ICAM-1 protein and the same is
true for costimulation with the Th2 cytokines IL-4 and
IL-13.90 At present, there is no published functional eval-
uation of these in vitro data on ICAM-1.
NEUTROPHIL-MOBILIZING FACTORS INCREASED 
IN NON-EPITHELIAL CELLS BY IL-17
It is now clear that IL-17 can increase neutrophil-
mobilizing factors in several non-epithelial stromal cells
of potential relevance for inflammation in the airways
and lungs. Thus, human venous endothelial cells, cells
that constitute a crucial barrier for the extravasation of
neutrophils, respond to human IL-17 by releasing IL-8
in vitro and this release is sensitive to a glucuorticoid
(hydrocortisone).3 Primary human lung fibroblasts, cells
that possess the potential to communicate with the
neutrophil locally in lung tissue, also respond to stimula-
tion with human IL-17 by producing and releasing IL-6
and IL-8 in vitro and the same is true for IL-6 release in
embryonic lung fibroblasts.83 Again, this response to
IL-17 appears to be sensitive to a glucocorticoid (dexa-
methasone).83 Interestingly, there is now also a pre-
liminary report indicating that human IL-17 stimulates
primary human airway smooth muscle cells to release
IL-8 in vitro and that this response is not sensitive to a
glucccorticoid.103 At present, there are no studies evalu-
ating the functional significance of these in vitro findings
in terms of neutrophil recruitment or activation.
ACCUMULATION OF NEUTROPHILS IN THE 
AIRWAYS AND LUNGS CAUSED BY IL-17 IN VIVO
Several in vivo studies on rodents have shown that local
administration of IL-17 protein from humans and
rodents causes a substantial accumulation of neutrophils
in the airways.3,80,102,104,105 This in vivo response to IL-17
seems to be protein specific, because pretreatment of
the IL-17 protein with a neutralizing anti-human IL-17
antibody attenuates its effect.3 In rodent airways, the
effect of IL-17 on neutrophil accumulation is as selective
as that of the Th1 cytokine IL-1β.104 One study indicates
that systemic pretreatment with a glucocorticoid (dexa-
methasone) attenuates the effect of IL-17 on neutrophil
accumulation.3
It has been shown previously that the concentration of
the rodent C-X-C chemokine macrophage inflammatory
protein (MIP)-2 is increased in the airways after stim-
ulation with IL-17 protein in vivo.3 In line with this, a
neutralizing anti-MIP-2 antibody does attenuate the
IL-17-induced accumulation of neutrophils in the air-
ways.3 There is now also evidence that the IL-17-induced
release of IL-6 plays a role similar to that of MIP-2 in the
accumulation of neutrophils in rodent airways.80 In addi-
tion, GM-CSF plays a role for the accumulation of
neutrophils caused by IL-17 and TNF-α in rodent airways
in vivo.102 It also appears as if endogenous tachykinins,
modulated by neutral endopeptidase and acting on NK1
receptors, facilitate the IL-17-induced accumulation of
neutrophils in rodent airways in vivo.104
There is evidence that IL-17 can activate accumulated
neutrophils in the airways in vivo.105 This effect may be medi-
ated mainly through indirect mechanisms, because local
administration of IL-17 protein causes an increase in
elastase and myeloperoxidase (MPO) activity in rodent
airways in vivo, but no corresponding effect is observed
when isolated blood neutrophils from rodents are stimu-
lated by IL-17 protein in vitro.105 In contrast with IL-17,
local administration of IL-1β protein does not increase
MPO or elastase activity, even though it does accumulate
as many neutrophils in rodent airways in vivo.105 Of note,
although, local administration of rodent IL-1β plus
human IL-17 substantially enhances the aforementioned
increase in elastase activity, without causing any any pro-
nounced additional increase in neutrophil accumulation.
INTERLEUKIN-17 IN AIRWAY AND LUNG 
INFLAMMATION
The evidence for a role for IL-17 in human airway and
lung disease is still limited. There is one study showing a
substantial increase in free soluble IL-17 protein in the
airways of healthy volunteers after exposure to organic
dust, in association with a dramatic, local accumulation
of neutrophils.84 Presumably this type of airway inflam-
mation represents the Th1 type.
There is also one study showing a modest increase in
free soluble IL-17 protein in the airways of patients with
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asthma, associated with an increase in immunoreactivity
for intracellular IL-17 protein in airway inflammatory
cells.83 It appears feasible that this type of airway inflam-
mation represents the Th2 type. There are no published
data yet on putative neutrophil activation associated with
the presence of IL-17 protein in human airways.
In addition to the data on human airways, there is now
an increasing amount of data on rodent airways in vivo,
compatible with IL-17 playing a role in the accumulation
of neutrophils in airway disease. Thus, rodents lacking
the receptor for IL-17 are more susceptiable to bacterial
airway infection caused by Klebsiella pneumonie than are
wild-type rodents and this is paralleled by a weakened
mobilization of neutrophils in the airways.106,107 In line
with this, local administration of endotoxin from
Escherichia coli requires the presence of endogenous IL-
17 protein in order to mobilize neutrophils in the air-
ways.80 It is also clear that local administration of this
endotoxin increases the concentration of IL-17 protein in
rodent airways in vivo, compatible with data from
another study showing that endotoxin from E. coli
increases the mRNA for IL-17 in rodent airways.80,108
Indeed, all these findings are compatible with IL-17 being
involved in airway inflammation of the Th1 type.
Interestingly, two recent studies on rodents in vivo lend
further support to an involvement of IL-17 protein in
airway inflammation of the Th2 type. One of these studies
demonstrates that allergen challenge increases the
mRNA for IL-17 in sensitized airways.109 This study also
indicates that endogenous IL-17 protein is required for
allergen-induced accumulation of neutrophils and that
endogenous IL-17 actually suppresses the local produc-
tion of IL-5. Finally, a second study suggests that endog-
enous IL-17 is involved in mediating allergen-induced
bronchial hyperreactivity because sensitized rodents
lacking the gene for endogenous IL-17 protein display
less reactivity to metacholine after allergen challenge
than sensitized wild-type rodents.110
FUTURE RESEARCH ON IL-17
In conclusion, there is substantial evidence that an
exaggerated accumulation and activation of neutrophils
is linked to the course of obstructive airway disease in
humans. There is also evidence of plausible pathogenetic
mechanisms involving the neutrophil in acute, severe
asthma and COPD. The cytokine IL-17 now emerges
as a candidate mediator for a link between the activa-
tion of certain T lymphocytes and the accumulation and
subsequent activation of neutrophils in airway and lung
disease, even though its specific role in obstructive
airway disease remains to be determined. Interleukin-17
appears to exert its neutrophil-orchestrating activity indi-
rectly, through stimulation of a number of local cells in
the airways and lungs, resulting in the subsequent produc-
tion and release of a variety of cytokines directly affecting
neutrophils. For these reasons, it appears important to
document the presence and concentrations of IL-17 in
patients with various degrees of obstructive airway dis-
ease, in clinically stable patients and in patients with acute
exacerbations. Data from these type of studies may reveal
whether targeting IL-17 is a plausible strategy for the
development of novel pharmacotherapeutic interventions
against obstructive airway disease.
ACKNOWLEDGMENTS
This work was supported the Swedish Heart–Lung Fund,
the Swedish Research Council (K2002–74X-09048-13A),
the Vårdal Foundation and Åke Wiberg’s Foundation.
No support, direct or indirect, was obtained from the
tobacco industry.
REFERENCES
1 Rouvier E, Luciani MF, Mattei MG, Denizof F, Golstein P.
CTLA-8, cloned from an activated T cell, bearing AU-rich
messenger RNA instability sequences, and homologous to
a herpes virus saimiri gene. J. Immunol. 1993; 150:
5445–56.
2 Yao Z, Painter SL, Fanslow WC et al. Human IL-17:
A novel cytokine derived from T cells. J. Immunol. 1995;
155: 5483–6.
3 Laan M, Cui ZH, Hoshino H et al. Neutrophil recruitment
by human IL-17 via C-X-C chemokine release in the
airways. J. Immunol. 1999; 162: 2347–52.
4 Fahy JV, Kim KW, Kim J, Liu J, Boushey HA. Prominent
neutrophilic inflammation in sputum from subjects with
asthma excacerbation. J. Allergy Clin. Immunol. 1995;
95: 843–52.
5 Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV.
Increased neutrophil numbers and IL-8 levels in airway
secretions in acute severe asthma. Clinical and biological
significance. Am. J. Respir. Crit. Care Med. 2000; 161:
1185–60.
6 Vignola AM, Bonanno A, Mirabella A et al. Increased
level of elastase and alpha 1-antitrypsin in sputum of
asthmatic patients. Am. J. Respir. Crit. Care Med. 1998;
157: 505–11.
7 Lamblin C, Gosset P, Tillie-Leblond I et al. Bronchial
neutrophilia in patients with noninfectious status asthmati-
cus. Am. J. Respir. Crit. Care Med. 1998; 157: 394–402.
NEUTROPHILS AND IL-17 179
8 Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF,
Barnes PJ. Neutrophilic inflammation in severe persitent
asthma. Am. J. Respir. Crit. Care Med. 1999; 160:
1532–9.
9 Wenzel SE, Schwartz LB, Langmack EL et al. Evidence
that severe asthma can be divided into two inflam-
matory subtypes with distinct physiologic and clinical
characteristics. Am. J. Respir. Crit. Care Med. 1999;
160: 1001–8.
10 Saetta M, Turato G, Facchini F et al. Inflammatory cells
in the bronchial glands of smokers with chronic bronchi-
tis. Am. J. Respir. Crit. Care Med. 1997; 156: 1633–9.
11 Riise GC, Ahlstedt S, Larsson S et al. Bronchial inflamma-
tion in chronic bronchitis assessed by measurement of cell
products in bronchial lavage fluid. Thorax 1995; 50:
360–5.
12 Balbi B, Bason C, Balleari E et al. Increased broncho-
alveolar granulocytes and granulocyte/colony-stimulating
factor during exacerbations of chronic bronchitis. Eur.
Respir. J. 1997; 10: 846–50.
13 Betsuyaku T, Nishimura M, Takeyabu K et al. Neutrophil
granule proteins in bronchoalveolar lavage fluid from
subjects with subclinical emphysema. Am. J. Respir. Crit.
Care Med. 1999; 159: 1985–91.
14 Aaron SD, Angel JB, Lunau M et al. Granulocyte inflam-
matory markers and airway infection during acute exacer-
bation of chronic obstructive pulmonary disease. Am. J.
Respir. Crit. Care Med. 2001; 163: 349–55.
15 Balzano G, Stefanelli F, Irorio C et al. Eosinophilic
inflammation in stable chronic obstructive pulmonary
disease. Am. J. Respir. Crit. Care Med. 1999; 160:
1486–92.
16 Di Stefano A, Capelli A, Lusardi M et al. Severity of airflow
limitation is associated with severity of airway inflamma-
tion in smokers. Am. J. Respir. Crit. Care Med. 1999;
158: 1277–85.
17 Soler N, Ewig S, Torres A, Filella X, Gonzales J, Zaubet A.
Airway inflammation and bronchial microbial patterns
in  patients with stable chronic obstructive pulmonary
disease. Eur. Respir. J. 1999; 14: 1015–22.
18 Noguera A, Batle S, Miralles C et al. Enhanced neutrophil
response in chronic obstructive pulmonary disease.
Thorax 2001; 56: 432–7.
19 Betz R, Kohlhaufl M, Kassner G et al. Increased sputum
IL-8 and IL-5 in asymptomatic non-specific hyper-
responsiveness. Lung 2001; 179: 119–33.
20 Stanescu D, Sanna A, Kostianev S, Calgagni PG, Fabbri
LM, Maestrelli P. Airway obstruction, chronic expectora-
tion, and rapid decline in FEV1 in smokers are associated
with increased levels of sputum neutrophils. Thorax 1996;
51: 267–71.
21 Fujimura M, Xiu Q, Tsujiura M et al. Role of leuko-
triene B4 in bronchial hyperresponsiveness induced by
interleukin-8. Eur. Respir. J. 1998; 11: 306–11.
22 Matsumoto K, Aizawa H, Inoue H, Koto H, Nakano H,
Hara N. Role of neutrophil elastase in ozone-induced
airway responses in guinea-pigs. Eur. Respir. J. 1999;
14: 1088–94.
23 Suzuki T, Wang W, Lin JT, Shirato K, Mitsuhashi H,
Inoue H. Aerosolised human neutrophil elastase induces
airway constriction and hyper-responsiveness with protec-
tion by intravenous pretreatment with half-length secretory
leukoprotease inhibitor. Am. J. Respir. Crit. Care Med.
1996; 153: 1405–11.
24 Chen XJ, Hedlund LW, Moller HE, Chawla MS,
Maronpot RR. Detection of emphysema in rat lungs by
using magnetic resonance measurements of 3He diffu-
sion. Proc. Natl Acad. Sci. USA 2000; 10: 11 478–81.
25 Zhu YK, Liu XD, Skold CM et al. Synergistic neutrophil
elastase–cytokine interaction degrades collagen in three
dimensional culture. Am. J. Physiol. Lung Cell. Mol.
Physiol. 2000; 281: L868–78.
26 Sampson AP. The role of eosinophils and neutrophils in
inflammation. Clin. Exp. Allergy 2000; 30: 22–7.
27 Schuster A, Ueki I, Nadel JA. Neutrophil elastase
stimulates tracheal submucosal gland secretion that is
inhibited by ICI 200,355. Am. J Physiol. 1992; 262:
L86–91.
28 Nadel JA, Takeyama K, Augusti C. Role of neutrophil
elastase in hypersecretion in asthma. Eur. Respir. J. 1999;
13: 190–6.
29 Culpitt AV, Maziak W, Loukidis S, Nightingale JA,
Matthews JL, Barnes PJ. Effect of high dose inhaled
steroid on cells, cytokines and proteases in induced
sputum in chronic obstructive pulmonary disease. Am. J.
Respir. Crit. Care Med. 1999; 160: 1635–9.
30 Prikk K, Maisis P, Pirila E et al. Airway obstruction cor-
relates with collagenase-2 (MMP-8) expression and
activation in bronchial asthma. Lab. Invest. 2002; 82:
1534–45.
31 Cataldo DD, Bettiol J, Noel A, Bartsch P, Foidart JM,
Lous R. Matrix metalloproteinase-9, but not tissue inhibi-
tor of matrix metalloproteinase-1, increases in the sputum
from allergic asthmatic patients after allergen challenge.
Chest 2002; 122: 1553–9.
32 Mattos W, Lim S, Russel R, Jatakanon A, Chung KF,
Barnes PJ. Matric metalloproteinase-9 expression in
asthma: Effect of asthma severity, allergen challenge, and
inhaled glucocorticoids. Chest 2002; 122: 1543–52.
33 Lee YC, Lee HB, Rhee YK, Song CH. The involvement
of matrix metalloproteinase-9 in airway inflammation of
patients with acute asthma. Clin. Exp. Allergy 2001; 31:
1623–30.
34 Cataldo D, Munuat C, Noel A et al. MMP-2- and MMP-
9-linked gelatinolytic activity in the sputum from patients
with asthma and chronic obstructive pulmonary disease.
Int. Arch. Allergy Immunol. 2000; 123: 259–67.
35 Cataldo DD, Tournoy KG, Vermaelen K et al. Matrix
metalloproteinase-9 deficiency impairs cellular infiltration
and bronchial hyperresponsiveness during allergen-
induced airway inflammation. Am. J. Pathol. 2002; 161:
491–8.
36 Watanabe M, Kaihatsu T, Miwa M, Maeda T. Ca2+/
calmodulin-dependent protein kinase II inhibitors potenti-
ate superoxide production in polymorphonuclear leuko-
cytes. J. Pharm. Pharmacol. 1999; 51: 295–300.
180 A LINDÉN
37 Cortijo J, Villagrasa V, Pons R et al. Bronchodilator and
anti-inflammatory activities of glaucine: In vitro studies on
human airway smooth muscle and polymorphonuclear
leukocytes. Br. J. Pharmacol. 1999; 127: 1641–51.
38 Sustiel AM, Joseph B, Rocklin RE, Borish L. Asthmatic
patients have neutophils that exhibit diminished respon-
siveness to adenosine. Am. Rev. Respir. Dis. 1989; 140:
1556–61.
39 Massion P, Lindén A, Inoue H, Mathy M, Grattan KM,
Nadel JA. Dimethyl sulfoxide decreases interleukin-8-
mediated neutrophil recruitment in the airways. Am. J.
Physiol. 1996; 271: L838–43.
40 Inoue H, Aizawa H, Nakano H et al. Nitric oxide synthase
inhibitors attenuate ozone-induced airway inflammation
in guinea pigs. Possible role of interleukin-8. Am. J.
Respir. Crit. Care Med. 2000; 161: 249–56.
41 Stevens WH, Inman MD, Wattie J, O’Byrne PM. Allergen-
induced oxygen radical release from bronchoalveolar
lavage cells and airway hyperresponsiveness in dogs.
Am. J. Respir. Crit. Care Med. 1995; 151: 1526–31.
42 Takahashi T, Miura M, Katsumata U et al. Involvement of
superoxide in ozone-induced airway hyperresponsiveness
inanaesthetized cats. Am. Rev. Respir. Dis. 1993; 148:
103–6.
43 Nakano H, Aizawa H, Matsumoto K, Fukuyama S,
Inoue H, Hara N. Cyclooxygenase-2 participates in the
late phase of airway hyperresponsiveness after ozone
exposure in guinea pigs. Eur. J. Pharmacol. 2000; 403:
267–75.
44 Matsui S, Jones GL, Woolley MJ, Lane CC, Gontovnick LS,
O’Byrne PM. The effect of antioxidants on ozone-induced
airway hyperresponsiveness in dogs. Am. Rev. Respir. Dis.
1991; 144: 1287–90.
45 Hallahan AR, Armour CL, Black JL. Products of neutro-
phils and eosinophils increase the responsiveness of
human isolated bronchial tissue. Eur. Respir. J. 1990; 3:
554–8.
46 Zeng L, Shum H, Tipoe GL et al. Macrophages, neutrophils
and tumor necrosis factor-alpha expression in bronchiec-
tatic airways in vivo. Respir. Med. 2001; 95: 792–8.
47 Volcano M, Alves Rosa MF, Minnucci FS, Chernavsky AC,
Isturiz MA. N-Formyl-methionyl-leucyl-phenylalanine (fMLP)
inhibits tumor necrosis factor-alpha (TNF-alpha) production
in lipopolysaccharide (LPS)-stimulated human neutrophils.
Clin. Exp. Immunol. 1998; 113: 39–47.
48 Page SM, Gleich GJ, Roebuck KA, Thomas LL. Stimula-
tion of neutrophil interleukin-8 production by eosinophil
granule major basic protein. Am. J. Respir. Cell. Mol.
Biol. 1999; 21: 230–7.
49 Keatings VM, Collins PD, Scott DM, Barnes PJ. Differ-
ences in interleukin-8 and tumor necrosis factor-alpha in
induced sputum from patients with chronic obstructive
pulmonary disease or asthma. Am. J. Respir. Crit. Care
Med. 1996; 153: 530–4.
50 Sibelius U, Hattar K, Hoffman S et al. Distinct pathways of
lipopolysaccharide priming of human neutrophil respira-
tory burst: Role of lipid mediator synthesis and sensitivity
to interleukin-10. Crit. Care Med. 2002; 30: 2306–12.
51 Gambero A, Landucci EC, Toyama MH et al. Human
neutrophil migration in vitro induced by secretory phos-
pholipases A2: A role for cell surface glycosaminoglycans.
Biochem. Pharmacol. 2002; 63: 65–72.
52 Falt J, Dahlgren C, Ridell M. Difference in neutrophil
cytokine production induced by pathogenic and non-
pathogenic mycobacteria. APMIS 2002; 110: 593–600.
53 Kuhns DB, Nelson EL, Alvord WG, Gallin JI. Fibrinogen
induces IL-8 synthesis in human neutrophils stimulated
with formyl-methionyl-leucyl-phenulalanine or leukotriene
B4. J. Immunol. 2001; 167: 2869–78.
54 Koller M, Wick M, Muhr G. Decreased leukotriene
release from neutrophils after severe trauma: Role of
immature cells. Inflammation 2001; 25: 53–9.
55 Xiu Q, Fujimura M, Nomura M et al. Bronchial hyper-
responsiveness and airway neutrophil accumulation
induced by interleukin-8 and the effect of the throm-
boxane A2 antagonist S-1452 in guinea-pigs. Clin. Exp.
Allergy 1995; 25: 51–9.
56 Hessel EM, Van Oosterhout AJ, Van Ark I et al. Develop-
ment of airway hyperresponsiveness is dependent on
interferon-gamma and independent of eosinophil infiltra-
tion. Am. J. Respir. Crit. Care Med. 1997; 160: 325–34.
57 Lindén A. Increased interleukin-8 release by beta-
adrenoceptor activation in human transformed bronchial
epithelial cells. Br. J. Pharmacol. 1996; 119: 402–6.
58 Jorens PG, Richman-Eisenstadt JBY, Housset BP et al.
Interleukin-8 induces neutrophil accumulation but not
protease secretion in the canine trachea. Am. J Physiol.
1992; 263: L708–13.
59 Amin K, Ludviksdottir D, Janson C et al. Inflammation and
structural changes in the airways of patients with atopic
and non-atopic asthma. Am. J. Respir. Crit. Care Med.
2000; 162: 2295–301.
60 Mazarella G, Grella E, D’Auria D et al. Phenotypic
features of alveolar monocytes/macrophages and IL-8
gene activation by IL-1 and TNF-alpha in asthmatic
patients. Allergy 2000; 55: 36–41.
61 Marini M, Vittori E, Hollemborg J, Mattoli S. Expression of
the potent inflammatory cytokines, granulocyte–macro-
phage-colony-stimulation factor and interleukin-6 and
interleukin-8, in bronchial epithelial cells of patients with
asthma. J. Allergy Clin. Immunol. 1992; 89: 1001–9.
62 Yousefi S, Hemmann S, Weber M et al. IL-8 is expressed
by human peripheral blood eosinophils: Evidence for
increased secretion in asthma. J. Immunol. 1995; 154:
5481–90.
63 Hoshi H, Ohno M, Hinma M et al. IL-5, IL-8 and GM-
CSF immunostaining of sputum cells in bronchial asthma
and chronic bronchitis. Clin. Exp. Allergy 1995; 25:
720–8.
64 Laitinen LA, Laitinen A, Haahtela T. Airway mucosal
inflammation even in patients with newly diagnosed
asthma. Am. Rev. Respir. Dis. 1993; 147: 697–704.
65 Gavett SH, Chen X, Finkelman F, Wills-Karp M. Depletion
of murine CD4+ T lymphocytes prevents antigen-induced
airway hyperreactivity and pulmonary eosinophilia. Am. J.
Respir. Cell Mol. Biol. 1994; 10: 587–93.
NEUTROPHILS AND IL-17 181
66 Renzi PM, Yang JP, Diamantstein T, Martin JG. Effects of
depletion of cells bearing the interleukin-2 receptor on
immunoglobulin production and allergic airway responses
in the rat. Am. J. Respir. Crit. Care Med. 1996; 153:
1214–21.
67 Rutgers SR, Postma DS, ten Hacken NH et al. Ongoing
airway inflammation in patients with COPD who do not
currently smoke. Thorax 2000; 55: 12–18.
68 Turato G, Zuin R, Monti S et al. Airway inflammation in
severe chronic obstructive pulmonary disease. Relation-
ship with lung function and radiologic emphysema. Am. J.
Respir. Crit. Care Med. 2002; 166: 105–10.
69 Meshi B, Vitalis TZ, Ionescu D et al. Emphysemateous
lung destruction by cigarette smoke. The effects of latent
adenoviral infection on the lung inflammatory response.
Am. J. Respir. Cell Mol. Biol. 2002; 26: 52–7.
70 Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells
and eosinophilia in bronchoalveolar lavages from
subjects with asthma correlated with disease severity.
J. Allergy Clin. Immunol. 1991; 88: 935–42.
71 Mishima H, Hojo M, Watanabe A, Hamid QA,
Martin JG. CD4+ T cells can induce airway hyper-
responsiveness to allergen challenge in the brown
Norway rat. Am. J. Respir. Crit. Care Med. 1998; 158:
1863–70.
72 De Sanctis GT, Itoh A, Green FHY et al. T-Lymphocytes
regulate genetically determined airway hyperresponsive-
ness in mice. Nat. Med. 1997; 4: 460–2.
73 Nakajima H, Iwamoto I, Tomoe S et al. CD4+ T-lym-
phocytes and interleukin-5 mediate antigen-induced eosi-
nophil infiltration into the mouse trachea. Am. Rev.
Respir. Dis. 1992; 146: 374–7.
74 Cieslewics G, Tomkinson A, Adler A et al. The late, but
not early, asthmatic response is dependent on IL-5 and
correlates with eosinophil infiltrarion. J. Clin. Invest.
1999; 104: 301–8.
75 Tillie-Leblond I, Hammad H, Desurmont S et al. CC
chemokines and interleukin-5 in bronchial lavage fluid
from patients with status asthmaticus. Potential implica-
tions in eosinophil recruitment. Am. J. Respir. Crit. Care
Med. 2000; 162: 586–92.
76 Leckie MJ, ten Brink A, Khan J et al. Effects of an
interleukin-5 blocking monoclonal antibody on eosino-
phils. Lancet 2000; 356: 2114–16.
77 Tomaki M, Zhao LL, Sjöstrand M, Lindén A, Ichinose M,
Lötvall J. Comparison of effects of anti-IL-3, IL-5 and
GM-CSF treatments on eosinophilopoesis and airway
eosinophilia induced by allergen. Pulmon. Pharmacol.
Ther. 2002; 15: 161–8.
78 Fossiez F, Banchereau J, Murray R, Van Kooten C,
Garrone P, Lebecque S. Interleukin-17. Intern. Rev.
Immunol. 1998; 16: 541–51.
79 Spriggs MK. Interleukin-17 and its receptor. J. Clin.
Immunol. 1997; 17: 366–9.
80 Miyamoto M, Prause O, Laan M, Sjöstrand M, Lötvall J,
Lindén A. Endogenous IL-17 mediates endotoxin-induced
airway neutrophilia in mice in vivo. J. Immunol. 2003;
170: 4665–72.
81 Shin H, Benbernou N, Esnault S, Guenounou M.
Expression of IL-17 in human memory CD45RO+
T lymphocytes and its regulation by protein kinase A
pathway. Cytokine 1999; 11: 257–66.
82 Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is
produced by some proinflammatory Th1/Th0 cells but not
Th2 cells. J. Immunol. 1999; 162: 1246–51.
83 Molet S, Hamid QA, Davoine F et al. Interleukin-17 is
increased in asthmatic airways and induces human
fibroblasts to produce cytokines. J. Allergy Clin. Immunol.
2001; 108: 103–9.
84 Laan M, Palmberg L, Larsson K, Linden A. Free, soluble
interleukin-17 protein during severe inflammation in
human airways. Eur. Respir. J. 2002; 19: 534–7.
85 Yao Z, Spriggs M, Derry J et al. Molecular characterisa-
tion of the human interleukin (IL)-17 receptor. Cytokine
1997; 9: 794–800.
86 Yao Z, Fanslow FC, Seldin MF et al. Herpesvirus Saimiri
encodes a new cytokine, IL-17, which binds to a novel
cytokine receptor. Immunity 1995; 3: 811–21.
87 Kehlen A, Thiele K, Rieman D, Langner J. Expression,
modulation and signalling of IL-17 recepor in fibroblast-
like synoviocytes of patients with rheumatoid arthritis.
Clin. Exp. Immunol. 2002; 127: 539–46.
88 Fossiez F, Djossou O, Chomarat P et al. T cell interleukin-
17 induces stromal cells to produce proinflammatory and
hematopoietic cytokines. J. Exp. Med. 1996; 183:
2593–603.
89 Laan M, Lötvall J, Chung KF, Lindén A. IL-17-induced
cytokine release in human bronchial epithelial cells in
vitro: Role of mitogen-activated protein (MAP) kinases. Br.
J. Pharmacol. 2001; 133: 200–6.
90 Kawaguchi M, Kokubu F, Kuga H et al. Modulation of
bronchial epithelial cells by IL-17. J. Allergy Clin. Immu-
nol. 2001; 108: 804–9.
91 Prause O, Laan M, Lotvall J, Lindén A. Pharmacological
modulation of interleukin-17-induced GCP-2-, GRO-α-
and interleukin-8 release in human bronchial epithelial
cells. Eur. J. Pharmacol. 2003; 462: 193–8.
92 Jones CE, Chan K. Interleukin-17 stimulates the expression
of interleukin-8, growth-related oncogene-α, and granu-
locyte-colony-stimulating factor by human airway epithelial
cells. Am. J. Respir. Cell Mol. Biol. 2002; 26: 748–53.
93 Cockroft DW, MacParland CP, Britto SA, Swystun VA,
Rutherford BC. Regular inhaled salbutamol and airway
responsiveness to allergen. Lancet 1993; 342: 833–7.
94 Cockroft DW, O’Byrne P, Swystun VA, Baghat R Regular
use of inhaled salbutamol and the allergen-induced late
asthmatic response. J. Allergy Clin. Immunol. 1995; 96:
44–9.
95 Kamachi A, Munakata M, Nasuhara Y et al. Enhance-
ment of goblet cell hyperplasia and airway hyperrespon-
siveness by salbutamol in a rat model of atopic asthma.
Thorax 2001; 56: 19–24.
96 Awane M, Andres PG, Li DJ, Reinecker HC. NF-κB-
inducing kinase is a common mediator of IL-17-, TNF-α-,
and IL-1β-induced chemokine promoter activation in intes-
tinal epithelial cells. J. Immunol. 1999; 162: 5337–44.
182 A LINDÉN
97 Mori N, Oishi K, Sar B et al. Essential role of transcription
factor nuclear factor-kappa B in regulation of interleukin-
8 gene expression by nitrite reductase from Pseudomonas
aeruginosa in respiratory epithelial cells. Infect. Immun.
1999; 67: 3872–8.
98 Harper R, Wu K, Chang MM et al. Activation of nuclear
factor-kappa B in airway epithelial cells by thioredoxin but
not N-acetylcysteine and glutathione. Am. J. Respir. Cell
Mol. Biol. 2001; 25: 178–85.
99 Chang MM, Harper R, Hyde DM, Wu R. A novel mecha-
nism of retinoic acid-enhanced interleukin-8 gene expres-
sion in airway epithelium. Am. J. Respir. Cell Mol. Biol.
2000; 22: 502–10.
100 Kennedy T, Ghio AJ, Reed W et al. Copper-dependent
inflammation and nuclear factor-kappa B activation by
particulate air pollution. Am. J. Respir. Cell Mol. Biol.
1998; 19: 366–78.
101 Mastronarde JG, Monick MM, Mukaida N,
Matsushima K, Hunninghake GW. Activator protein-1 is
the preferred transcription factor for cooperative inter-
action with nuclear factor-kappa B in respiratory syncytial
virus-induced interleukin-8 gene expression in airway
epithelium. J. Infect. Dis. 1998; 177: 1275–81.
102 Laan M, Prause O, Miyamoto M et al. A role of GM-CSF
in the accumulation of neutrophils in the airways caused
by IL-17 and TNF-alpha. Eur. Respir. J. 2003; 21: 1–7.
103 Vanaudenaerde BM, Wuyts WA, Dupont LJ, Demetdts MG,
Raemdonck DV, Verleden GM. The possible role of
human airway smooth muscle cells (HASMC) in the
pathogenesis of obliterative bronchiolitis after lung trans-
plantation. Eur. Respir. J. 2002; 20 (Suppl. 38): S348
(Abstract).
104 Hoshino H, Lötvall J, Skoogh BE, Lindén A. Neutrophil
recruitment by IL-17 into rat airways in vivo: Role of
tachykinins. Am. J. Respir. Crit. Care Med. 1999; 159:
1423–8.
105 Hoshino H, Laan M, Sjöstrand M, Lötvall J, Skoogh BE,
Lindén A. Increased elastase and myeloperoxidase activ-
ity associated with neutrophil recruitment by IL-17 in
airways in vivo. J. Allergy Clin. Immunol. 2000; 105:
143–9.
106 Ye P, Rodriguez FH, Kanaly S et al. Requirement of
interleukin 17 receptor signaling for lung CXC chemokine
and granulocyte colony-stimulating factor expression,
neutrophil recruitment, and host defense. J. Exp. Med.
2001; 194: 519–27.
107 Ye P, Garvey PB, Zhang P, Nelson S, Bagby G,
Summer WR, Schwarzenberger P, Shellito JE, Kolls JK.
Interleukin-17 and lung host defense against Klebisella
pneumonie infection. Am. J. Respir. Crit. Care Med.
2001; 25: 335–40.
108 Larsson R, Rocksén D, Lillienhook B, Jonsson A, Bucht A.
Dose-dependent activation of lymphocytes in endotoxin-
induced airway inflammation. Infect. Immun. 2000; 68:
6962–9.
109 Hellings PW, Kasran A, Liu Z et al. Interleukin-17 orches-
trates the granulocyte influx into airways after allergen
inhalation in a mouse model of allergic asthma. Am. J.
Respir. Crit. Care Med. 2003; 28: 42–50.
110 Nakae S, Komiyama Y, Nambu A et al. Antigen-specific
T cell sensitization is impaired in IL-17-deficient mice,
causing suppression of allergic cellular and humoral
responses. Immunity 2002; 17: 375–87.
